Annual CFF
$848.00 K
-$2.15 M-71.71%
December 31, 2023
Summary
- As of February 7, 2025, CYCC annual cash flow from financing activities is $848.00 thousand, with the most recent change of -$2.15 million (-71.71%) on December 31, 2023.
- During the last 3 years, CYCC annual CFF has fallen by -$28.66 million (-97.13%).
- CYCC annual CFF is now -98.58% below its all-time high of $59.62 million, reached on December 31, 2004.
Performance
CYCC Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$1000.00
-$6.29 M-100.02%
September 30, 2024
Summary
- As of February 7, 2025, CYCC quarterly cash flow from financing activities is -$1000.00, with the most recent change of -$6.29 million (-100.02%) on September 30, 2024.
- Over the past year, CYCC quarterly CFF has dropped by -$1.00 million (-100.10%).
- CYCC quarterly CFF is now -100.00% below its all-time high of $39.01 million, reached on June 30, 2006.
Performance
CYCC Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$7.21 M
+$49.00 K+0.68%
September 30, 2024
Summary
- As of February 7, 2025, CYCC TTM cash flow from financing activities is $7.21 million, with the most recent change of +$49.00 thousand (+0.68%) on September 30, 2024.
- Over the past year, CYCC TTM CFF has increased by +$6.36 million (+750.00%).
- CYCC TTM CFF is now -89.88% below its all-time high of $71.24 million, reached on March 31, 2007.
Performance
CYCC TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CYCC Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -71.7% | -100.1% | +750.0% |
| 3 y3 years | -97.1% | +98.0% | +140.4% |
| 5 y5 years | +97.7% | +98.0% | +140.4% |
CYCC Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -96.1% | at low | -100.0% | +98.7% | -66.8% | +6712.8% |
| 5 y | 5-year | -97.1% | at low | -100.0% | +98.7% | -84.8% | +2893.8% |
| alltime | all time | -98.6% | +168.5% | -100.0% | +99.8% | -89.9% | +682.2% |
Cyclacel Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1000.00(-100.0%) | $7.21 M(+0.7%) |
| Jun 2024 | - | $6.29 M(-8060.8%) | $7.16 M(+774.1%) |
| Mar 2024 | - | -$79.00 K(-107.9%) | $819.00 K(-3.4%) |
| Dec 2023 | $848.00 K(-71.7%) | $999.00 K(-2098.0%) | $848.00 K(-878.0%) |
| Sep 2023 | - | -$50.00 K(-2.0%) | -$109.00 K(-107.4%) |
| Jun 2023 | - | -$51.00 K(+2.0%) | $1.47 M(-50.9%) |
| Mar 2023 | - | -$50.00 K(-219.0%) | $3.00 M(0.0%) |
| Dec 2022 | $3.00 M(-86.2%) | $42.00 K(-97.3%) | $3.00 M(-22.0%) |
| Sep 2022 | - | $1.53 M(+3.9%) | $3.84 M(-26.3%) |
| Jun 2022 | - | $1.47 M(-3048.0%) | $5.21 M(+41.3%) |
| Mar 2022 | - | -$50.00 K(-105.6%) | $3.69 M(-83.0%) |
| Dec 2021 | $21.74 M(-26.3%) | $887.00 K(-69.5%) | $21.74 M(-32.5%) |
| Sep 2021 | - | $2.90 M(-5794.1%) | $32.20 M(+10.1%) |
| Jun 2021 | - | -$51.00 K(-100.3%) | $29.24 M(-38.5%) |
| Mar 2021 | - | $18.00 M(+58.6%) | $47.55 M(+61.2%) |
| Dec 2020 | $29.50 M(+666.7%) | $11.35 M(<-9900.0%) | $29.50 M(+63.0%) |
| Sep 2020 | - | -$50.00 K(-100.3%) | $18.11 M(+0.0%) |
| Jun 2020 | - | $18.26 M(<-9900.0%) | $18.10 M(-7115.1%) |
| Mar 2020 | - | -$50.00 K(0.0%) | -$258.00 K(-106.7%) |
| Dec 2019 | $3.85 M(+797.0%) | -$50.00 K(-12.3%) | $3.85 M(-14.1%) |
| Sep 2019 | - | -$57.00 K(-43.6%) | $4.48 M(-0.2%) |
| Jun 2019 | - | -$101.00 K(-102.5%) | $4.49 M(-1.1%) |
| Mar 2019 | - | $4.06 M(+599.3%) | $4.54 M(+957.1%) |
| Dec 2018 | $429.00 K(-97.1%) | $580.00 K(-1260.0%) | $429.00 K(<-9900.0%) |
| Sep 2018 | - | -$50.00 K(-2.0%) | -$3000.00(-100.0%) |
| Jun 2018 | - | -$51.00 K(+2.0%) | $13.69 M(-6.7%) |
| Mar 2018 | - | -$50.00 K(-133.8%) | $14.66 M(-0.6%) |
| Dec 2017 | $14.75 M(+123.7%) | $148.00 K(-98.9%) | $14.75 M(-8.4%) |
| Sep 2017 | - | $13.64 M(+1372.8%) | $16.10 M(+114.6%) |
| Jun 2017 | - | $926.00 K(+2472.2%) | $7.50 M(+12.3%) |
| Mar 2017 | - | $36.00 K(-97.6%) | $6.68 M(+1.3%) |
| Dec 2016 | $6.59 M(-39.3%) | $1.50 M(-70.2%) | $6.59 M(+19.3%) |
| Sep 2016 | - | $5.04 M(+4743.3%) | $5.53 M(+739.7%) |
| Jun 2016 | - | $104.00 K(-308.0%) | $658.00 K(+54.1%) |
| Mar 2016 | - | -$50.00 K(-111.5%) | $427.00 K(-96.1%) |
| Dec 2015 | $10.86 M(-11.0%) | $434.00 K(+155.3%) | $10.86 M(-8.1%) |
| Sep 2015 | - | $170.00 K(-233.9%) | $11.81 M(+1.9%) |
| Jun 2015 | - | -$127.00 K(-101.2%) | $11.59 M(-44.7%) |
| Mar 2015 | - | $10.38 M(+649.7%) | $20.96 M(+71.8%) |
| Dec 2014 | $12.20 M(-55.4%) | $1.39 M(-2870.0%) | $12.20 M(-4.4%) |
| Sep 2014 | - | -$50.00 K(-100.5%) | $12.77 M(-19.7%) |
| Jun 2014 | - | $9.24 M(+468.2%) | $15.89 M(-38.1%) |
| Mar 2014 | - | $1.63 M(-16.7%) | $25.67 M(-6.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | $27.33 M(+587.6%) | $1.95 M(-36.6%) | $27.33 M(+3.4%) |
| Sep 2013 | - | $3.08 M(-83.8%) | $26.42 M(+13.1%) |
| Jun 2013 | - | $19.02 M(+478.9%) | $23.36 M(+441.3%) |
| Mar 2013 | - | $3.29 M(+215.6%) | $4.32 M(+8.6%) |
| Dec 2012 | $3.98 M(-55.4%) | $1.04 M(+7335.7%) | $3.98 M(+35.1%) |
| Sep 2012 | - | $14.00 K(-156.0%) | $2.94 M(-76.0%) |
| Jun 2012 | - | -$25.00 K(-100.8%) | $12.27 M(+1.3%) |
| Mar 2012 | - | $2.94 M(>+9900.0%) | $12.11 M(+36.0%) |
| Dec 2011 | $8.91 M(-73.3%) | $9000.00(-99.9%) | $8.91 M(-61.3%) |
| Sep 2011 | - | $9.34 M(-5259.1%) | $23.01 M(+52.4%) |
| Jun 2011 | - | -$181.00 K(-30.4%) | $15.10 M(-2.8%) |
| Mar 2011 | - | -$260.00 K(-101.8%) | $15.54 M(-53.5%) |
| Dec 2010 | $33.40 M(+842.1%) | $14.11 M(+889.1%) | $33.40 M(+64.8%) |
| Sep 2010 | - | $1.43 M(+451.0%) | $20.27 M(-6.6%) |
| Jun 2010 | - | $259.00 K(-98.5%) | $21.71 M(+1.2%) |
| Mar 2010 | - | $17.60 M(+1686.4%) | $21.45 M(+505.0%) |
| Dec 2009 | $3.54 M(-386.3%) | $985.00 K(-65.6%) | $3.54 M(+57.3%) |
| Sep 2009 | - | $2.87 M(>+9900.0%) | $2.25 M(-344.6%) |
| Jun 2009 | - | $0.00(-100.0%) | -$921.00 K(-25.0%) |
| Mar 2009 | - | -$307.00 K(0.0%) | -$1.23 M(-0.8%) |
| Dec 2008 | -$1.24 M(-103.8%) | -$307.00 K(0.0%) | -$1.24 M(+0.2%) |
| Sep 2008 | - | -$307.00 K(0.0%) | -$1.24 M(0.0%) |
| Jun 2008 | - | -$307.00 K(-3.2%) | -$1.24 M(+13.4%) |
| Mar 2008 | - | -$317.00 K(+4.3%) | -$1.09 M(-103.4%) |
| Dec 2007 | $32.21 M(-43.9%) | -$304.00 K(-1.0%) | $32.21 M(+0.2%) |
| Sep 2007 | - | -$307.00 K(+90.7%) | $32.13 M(+0.2%) |
| Jun 2007 | - | -$161.00 K(-100.5%) | $32.06 M(-55.0%) |
| Mar 2007 | - | $32.98 M(-8801.8%) | $71.24 M(+24.1%) |
| Dec 2006 | $57.40 M(+587.1%) | -$379.00 K(+0.8%) | $57.40 M(+0.4%) |
| Sep 2006 | - | -$376.00 K(-101.0%) | $57.14 M(-14.3%) |
| Jun 2006 | - | $39.01 M(+103.8%) | $66.69 M(+141.6%) |
| Mar 2006 | - | $19.14 M(-3114.3%) | $27.60 M(+230.4%) |
| Dec 2005 | $8.35 M(-86.0%) | -$635.00 K(-106.9%) | $8.35 M(-77.6%) |
| Sep 2005 | - | $9.16 M(<-9900.0%) | $37.22 M(+26.9%) |
| Jun 2005 | - | -$68.00 K(-37.0%) | $29.34 M(-0.6%) |
| Mar 2005 | - | -$108.00 K(-100.4%) | $29.52 M(-50.5%) |
| Dec 2004 | $59.62 M(+366.6%) | $28.23 M(+2095.1%) | $59.62 M(+34.3%) |
| Sep 2004 | - | $1.29 M(+1008.6%) | $44.39 M(+3.2%) |
| Jun 2004 | - | $116.00 K(-99.6%) | $43.01 M(+0.4%) |
| Mar 2004 | - | $29.98 M(+130.7%) | $42.84 M(+235.3%) |
| Dec 2003 | $12.78 M | $13.00 M(<-9900.0%) | $12.78 M(-5829.1%) |
| Sep 2003 | - | -$93.00 K(+86.0%) | -$223.00 K(+71.5%) |
| Jun 2003 | - | -$50.00 K(-37.5%) | -$130.00 K(+62.5%) |
| Mar 2003 | - | -$80.00 K | -$80.00 K |
FAQ
- What is Cyclacel Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual CFF year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly CFF year-on-year change?
- What is Cyclacel Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals TTM CFF year-on-year change?
What is Cyclacel Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of CYCC is $848.00 K
What is the all time high annual CFF for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual cash flow from financing activities is $59.62 M
What is Cyclacel Pharmaceuticals annual CFF year-on-year change?
Over the past year, CYCC annual cash flow from financing activities has changed by -$2.15 M (-71.71%)
What is Cyclacel Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of CYCC is -$1000.00
What is the all time high quarterly CFF for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly cash flow from financing activities is $39.01 M
What is Cyclacel Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, CYCC quarterly cash flow from financing activities has changed by -$1.00 M (-100.10%)
What is Cyclacel Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of CYCC is $7.21 M
What is the all time high TTM CFF for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high TTM cash flow from financing activities is $71.24 M
What is Cyclacel Pharmaceuticals TTM CFF year-on-year change?
Over the past year, CYCC TTM cash flow from financing activities has changed by +$6.36 M (+750.00%)